RTOG 9404 RADIOTHERAPY WITH/WITHOUT BUDR + PROCARBAZINE, CCNU, AND VINCRISTINE

RTOG 9404 使用/不使用 BUDR 丙卡巴嗪、CCNU 和长春新碱的放射治疗

• 批准号: 6244484
• 负责人: JAMES RUFFER
• 金额: $ 2.36万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-17 至 1998-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244484
• 关键词: bromodeoxyuridine; clinical research; clinical trials; combination cancer therapy; drug screening /evaluation; glioblastoma multiforme; human subject; human therapy evaluation; lomustine; long term survivor; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; outcomes research; procarbazine; radiosensitizer; vincristine

BUdR is an agent which may make tumor tissue more receptive to treatment with radiation. This study will determine if the experimental drug BUdR given before and during radiation therapy, followed by the chemotherapy drugs procarbazine, CCNU, and vincristine can slow the growth of tumors. It will compare the efficacy of treatment with radiotherapy and PCV chemotherapy versus radiotherapy plus BUdR and PCV chemotherapy. The endpoints for this evaluation will be: Time to disease recurrence or progression, measured from the first day of treatment; Response rates and disease stabilization rates; Survival time, measured from the first day of treatment; and Activity level as determined by Karnofsky Performance Status.

BUdR是一种可以使肿瘤组织更容易接受治疗的药物 用辐射。 这项研究将确定实验药物BUdR 在放射治疗之前和期间给予，然后是化疗， 药物甲基苄肼、环己亚硝脲和长春新碱可以减缓肿瘤的生长。 将比较放射治疗和PCV治疗的疗效 化疗与放疗加BUdR和PCV化疗的比较。 的 本评价的终点为：至疾病复发的时间或 进展，从治疗第一天开始测量;缓解率和 疾病稳定率;生存时间，从第一天开始测量 处理;和通过Karnofsky Performance测定的活性水平 Status.